Prediagnostic body mass index trajectories in relation to prostate cancer incidence and mortality in the PLCO cancer screening trial

Journal of the National Cancer Institute

Volumn 109, Issue 3, 2017, Pages

  Kelly, Scott P ^a,b   Graubard, Barry I ^a   Andreotti, Gabriella ^a   Younes, Naji ^b   Cleary, Sean D ^b   Cook, Michael B ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b GEORGE WASHINGTON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; BODY MASS; CANCER INCIDENCE; CANCER MORTALITY; CANCER RISK; CANCER SCREENING; CARCINOGENESIS; COHORT ANALYSIS; CONTROLLED STUDY; FATALITY; HUMAN; MAJOR CLINICAL STUDY; MALE; OBESITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; WEIGHT CHANGE; WEIGHT GAIN; BLOOD; COMPLICATION; EARLY CANCER DIAGNOSIS; FOLLOW UP; MASS SCREENING; METABOLISM; MIDDLE AGED; MORTALITY; PROCEDURES; PROPORTIONAL HAZARDS MODEL; PROSTATIC NEOPLASMS; QUESTIONNAIRE; RISK FACTOR; TREATMENT OUTCOME;

PROSTATE SPECIFIC ANTIGEN;

AGED; BODY MASS INDEX; EARLY DETECTION OF CANCER; FOLLOW-UP STUDIES; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; OBESITY; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RISK FACTORS; SURVEYS AND QUESTIONNAIRES; TREATMENT OUTCOME;

EID: 85018172763     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djw225     Document Type: Article

References (59)

1. Flegal KM, Carroll MD, Kit BK, et al. Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999-2010. JAMA. 2012; 307(5):491-497.
2. Finucane MM, Stevens GA, Cowan MJ, et al. National, regional, and global trends in body-mass index since 1980: Systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9.1 million participants. Lancet. 2011;377(9765):557-567.
3. Allott EH, Masko EM, Freedland SJ. Obesity and prostate cancer: Weighing the evidence. Eur Urol. 2013;63(5):800-809.
4. Cao Y, Ma J. Body Mass Index, Prostate cancer-specific mortality, and biochemical recurrence: A systematic review and meta-analysis. Cancer Prev Res. 2011;4(4):486-501.
5. Zhong S, Yan X, Wu Y, et al. Body mass index and mortality in prostate cancer patients: A dose-response meta-analysis. Prostate Cancer Prostatic Dis. 2016;19(2):122-31.
6. Chen Q, Chen T, Shi W, et al. Adult weight gain and risk of prostate cancer: A dose-response meta-analysis of observational studies. Int J Cancer. 2016; 138(4):866-874.
7. Freedland SJ, Platz EA. Obesity and prostate cancer: Making sense out of apparently conflicting data. Epidemiol Rev. 2007;29:88-97.
8. Bianchini F, Kaaks R, Vainio H. Overweight, obesity, and cancer risk. Lancet Oncol. 2002;3(9):565-574.
9. MacInnis RJ, English DR. Body size and composition and prostate cancer risk: Systematic review and meta-regression analysis. Cancer Causes Control. 2006; 17(8):989-1003.
10. Andersson SO, Baron J, Wolk A, et al. Early-life risk-factors for prostatecancer - A population-based case-control study in Sweden. Cancer Epidemiol Biomarkers Prev. 1995;4(3):187-192.
11. Robinson WR, Stevens J, Gammon MD, et al. Obesity before age 30 years and risk of advanced prostate cancer. Am J Epidemiol. 2005;161(12): 1107-1114.
12. Robinson WR, Poole C, Godley PA. Systematic review of prostate cancer's association with body size in childhood and young adulthood. Cancer Causes Control. 2008;19(8):793-803.
13. Sutcliffe S, Colditz GA. Prostate cancer: Is it time to expand the research focus to early-life exposures?. Nat Rev Cancer. 2013;13(3):208-218.
14. Sakr WA, Haas GP, Cassin BF, et al. The frequency of carcinoma and intraepithelial neoplasia of the prostate in young male-patients. J Urol. 1993;150(2): 379-385.
15. Keum N, Greenwood DC, Lee DH, et al. Adult weight gain and adiposityrelated cancers: A dose-response meta-analysis of prospective observational studies. J Natl Cancer Inst. 2015;107(2). doi: 10.1093/jnci/djv088.
16. Giovannucci E, Michaud D. The role of obesity and related metabolic disturbances in cancers of the colon, prostate, and pancreas. Gastroenterology. 2007; 132(6):2208-2225.
17. Renehan AG, Roberts DL, Dive C. Obesity and cancer: Pathophysiological and biological mechanisms. Arch Physiol Biochem. 2008;114(1):71-83.
18. Prorok PC, Andriole GL, Bresalier RS, et al. Design of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Controlled Clinical Trials. 2000;21(6):273s-309s.
19. Nagin DS. Analyzing developmental trajectories: A semiparametric, groupbased approach. Psychol Methods. 1999;4(2):139-157.
20. Miller AB, Yurgalevitch S, Weissfeld JL, et al. Death review process in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Controlled Clinical Trials. 2000;21(6):400s-406s.
21. Korn EL, Graubard BI, Midthune D. Time-to-event analysis of longitudinal follow-up of a survey: Choice of the time-scale. Am J Epidemiol. 1997;145(1): 72-80.
22. Cox DR. Regression models and life-tables. J Royal Stat Soc Series B Stat Methodol. 1972;34(2):187-220.
23. Gail MH, Graubard B, Williamson DE, et al. Comments on "Choice of time scale and its effect on significance of predictors in longitudinal studies.". Stat Med. 2009;28(8):1315-1317.
24. Breslow NE, Day NE. Statistical Methods in Cancer Research, Vol. II-The Design and Analysis of Cohort Studies. Lyon, France: International Agency for Research on Cancer; 1987.
25. Nagin DS, Odgers CL. Group-based trajectory modeling in clinical research. Annu Rev Clin Psychol. 2010;6:109-138.
26. Jones BL, Nagin DS. Advances in group-based trajectory modeling and an SAS procedure for estimating them. Soc Methods Res. 2007;35(4):542-571.
27. OldhamPD. A note on analysis of repeated measurements of same subjects. J Chron Dis. 1962;15(Oct):969-977.
28. Gilthorpe MS, Tu YK. Mathematical coupling: A multilevel approach. Int J Epidemiol. 2004;33(6):1399-1400.
29. Tu YK, Baelum V, Gilthorpe MS. The problem of analysing the relationship between change and initial value in oral health research. Eur J Oral Sci. 2005; 113(4):271-278.
30. Blomqvist N. On the bias caused by regression toward the mean in studying the relation between change and initial value. J Clin Periodontol. 1987;14(1):34-37.
31. Glymour MM, Weuve J, Berkman LF, et al. When is baseline adjustment useful in analyses of change? An example with education and cognitive change. Am J Epidemiol. 2005;162(3):267-278.
32. Zheng H, Tumin D, Qian Z. Obesity and mortality risk: new findings from body mass index trajectories. Am J Epidemiol. 2013;178(11):1591-1599.
33. Song M, Willett WC, Hu FB, et al. Trajectory of body shape across the lifespan and cancer risk. Int J Cancer. 2016;138(10):2383-2395.
34. Bassett JK, Severi G, Baglietto L, et al. Weight change and prostate cancer incidence and mortality. Int J Cancer. 2012;131(7):1711-1719.
35. Hernandez BY, Park SY, Wilkens LR, et al. Relationship of body mass, height, and weight gain to prostate cancer risk in the multiethnic cohort. Cancer Epidemiol Biomarkers Prev. 2009;18(9):2413-2421.
36. Wright ME, Chang SC, Schatzkin A, et al. Prospective study of adiposity and weight change in relation to prostate cancer incidence and mortality. Cancer. 2007;109(4):675-684.
37. Tilling K, Howe LD, Ben-Shlomo Y. Commentary: Methods for analysing life course influences on health-untangling complex exposures. Int J Epidemiol. 2011;40(1):250-252.
38. Moller E, Adami HO, Mucci LA, et al. Lifetime body size and prostate cancer risk in a population-based case-control study in Sweden. Cancer Causes Control. 2013;24(12):2143-2155.
39. Ma J, Li HJ, Giovannucci E, et al. Prediagnostic body-mass index, plasma Cpeptide concentration, and prostate cancer-specific mortality in men with prostate cancer: A long-term survival analysis. Lancet Oncol. 2008;9(11): 1039-1047.
40. Giovannucci E, Rimm EB, Stampfer MJ, et al. Height, body weight, and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev. 1997;6(8):557-563.
41. Giovannucci E, Rimm EB, Liu Y, et al. Body mass index and risk of prostate cancer in US health professionals. J Natl Cancer Inst. 2003;95(16):1240-1244.
42. Moller E, Wilson KM, Batista JL, et al. Body size across the life course and prostate cancer in the Health Professionals Follow-up Study. Int J Cancer. 2016;138(4):853-865.
43. Renehan AG, Tyson M, Egger M, et al. Body-mass index and incidence of cancer: A systematic review and meta-analysis of prospective observational studies. Lancet. 2008;371(9612):569-578.
44. Renehan AG, Zwahlen M, Egger M. Adiposity and cancer risk: New mechanistic insights from epidemiology. Nature Reviews Cancer. 2015;15(8):484-498.
45. Hsing AW, Gao YT, Chua S, et al. Insulin resistance and prostate cancer risk. J Natl Cancer Inst. 2003;95(1):67-71.
46. Albanes D, Weinstein SJ, Wright ME, et al. Serum insulin, glucose, indices of insulin resistance, and risk of prostate cancer. J Natl Cancer Inst. 2009;101(18): 1272-1279.
47. Rowlands MA, Gunnell D, Harris R, et al. Circulating insulin-like growth factor peptides and prostate cancer risk: A systematic review and meta-analysis. Int J Cancer. 2009;124(10):2416-2429.
48. De Marzo AM, Platz EA, Sutcliffe S, et al. Inflammation in prostate carcinogenesis. Nat Rev Cancer. 2007;7(4):256-269.
49. Platz EA, De Marzo AM. Epidemiology of inflammation and prostate cancer. J Urol. 2004;171(2 Pt 2):S36-S40.
50. Osborn O, Olefsky JM. The cellular and signaling networks linking the immune system and metabolism in disease. Nat Med. 2012;18(3):363-374.
51. Williams G. Aromatase up-regulation, insulin and raised intracellular oestrogens in men, induce adiposity, metabolic syndrome and prostate disease, via aberrant ER-alpha and GPER signalling. Mol Cell Endocrinol. 2012;351(2): 269-278.
52. Schnoeller T, Jentzmik F, Rinnab L, et al. Circulating free testosterone is an independent predictor of advanced disease in patients with clinically localized prostate cancer. World J Urol. 2013;31(2):253-259.
53. TheoretMR, Ning YM, Zhang JJ, et al. The risks and benefits of 5 alpha-reductase inhibitors for prostate cancer prevention. N Engl J Med. 2011;365(2):97-99.
54. Gorber SC, Tremblay M, Moher D, et al. Diagnostic in obesity comorbidities -A comparison of direct vs. self-report measures for assessing height, weight and body mass index: A systematic review. Obes Rev. 2007;8(4):307-326.
55. Rimm EB, Stampfer MJ, Colditz GA, et al. Validity of self-reported waist and hip circumferences in men and women. Epidemiology. 1990;1(6):466-473.
56. Dahl AK, Hassing LB, Fransson EI, et al. Agreement between self-reported and measured height, weight and body mass index in old age-a longitudinal study with 20 years of follow-up. Age Ageing. 2010;39(4):445-451.
57. Dahl AK, Reynolds CA. Accuracy of recalled body weight-a study with 20-years of follow-up. Obesity. 2013;21(6):1293-1298.
58. Spencer EA, Appleby PN, Davey GK, et al. Validity of self-reported height and weight in 4808 EPIC-Oxford participants. Public Health Nutr. 2002;5(4):561-565.
59. Flegal KM, Troiano RP. Changes in the distribution of body mass index of adults and children in the US population. Int J Obes. 2000;24(7):807-818.